Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-03-02

Study Completion Date

2024-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies

NCT05315583

COVID-19 SARS CoV 2 Infection

TERMINATED NA

Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.

NCT04596098

SARS-CoV 2

COMPLETED

Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection

NCT04750720

Covid19 SARS-CoV-2

COMPLETED NA

Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study

NCT04888793

Covid19 COVID-19 Vaccines

COMPLETED

SARS-CoV-2 Antibodies and Virus Neutralisation in a Cohort Vaccinted Against COVID-19

NCT04979871

Vaccine Reaction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Convalescent Plasma Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient
* Immunocompromised patient (solid neoplasia, malignant hemopathy, solid organ transplantation, primary immune deficiency, systemic disease, chronic inflammatory disease, etc.)
* Hospitalized between 25/02/2020 and 15/01/2023 at HUS, ICANS, CH Colmar and CH Mulhouse
* Having received curative monoclonal antibody treatment or convalescent plasma treatment for SARS-Cov2 infection
* Patient who has not expressed, after being informed, his opposition to the reuse of his data for scientific research purposes.